報價延遲最少15分鐘:2026/04/18 06:37 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.81 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.93/0.23
|
|
企業價值
1.02B
|
| 資產負債 |
|
每股賬面淨值
10.12
|
| 現金流量 |
|
現金流量率
0.35
|
| 損益表 |
|
收益
705.20M
|
|
每股收益
20.79
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consistingof Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others. |
